ICU Medical (NASDAQ:ICUI) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of ICU Medical (NASDAQ:ICUI) in a research note issued to investors on Wednesday morning,Benzinga reports.

Several other analysts also recently issued reports on ICUI. StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. KeyCorp raised their price target on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Jefferies Financial Group started coverage on shares of ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 target price for the company. Finally, Raymond James raised their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Trading Down 1.8 %

NASDAQ ICUI opened at $174.81 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $4.27 billion, a P/E ratio of -38.25 and a beta of 0.66. ICU Medical has a 52-week low of $82.82 and a 52-week high of $196.26. The firm has a 50-day moving average price of $176.11 and a 200 day moving average price of $141.98.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.04%. The business had revenue of $580.07 million during the quarter, compared to the consensus estimate of $574.77 million. Equities research analysts expect that ICU Medical will post 3.81 EPS for the current year.

Insider Activity

In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, November 1st. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,973,261.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at $17,973,261.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,502 shares of company stock worth $8,445,976. 6.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ICUI. Scout Investments Inc. increased its holdings in ICU Medical by 16.3% in the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock valued at $5,463,000 after buying an additional 7,272 shares during the last quarter. SG Americas Securities LLC raised its position in shares of ICU Medical by 441.7% during the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after acquiring an additional 4,744 shares in the last quarter. Sei Investments Co. lifted its stake in ICU Medical by 52.1% during the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock worth $3,068,000 after purchasing an additional 9,793 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after purchasing an additional 145,485 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in ICU Medical by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after purchasing an additional 11,991 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.